Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

[1]  Stephen Broderick,et al.  Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer , 2018, The New England journal of medicine.

[2]  J. Bennink,et al.  PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8+ T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination , 2017, The Journal of Immunology.

[3]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[4]  P. Ascierto,et al.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma , 2017, The New England journal of medicine.

[5]  A. Hauschild,et al.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.

[6]  M. Atkins,et al.  Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. , 2017, The Lancet. Oncology.

[7]  J. Lunceford,et al.  IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.

[8]  S. Linn,et al.  Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies , 2017, Drugs.

[9]  J. Larkin,et al.  Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. , 2017, The oncologist.

[10]  E. Rozeman,et al.  Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  M. Smyth,et al.  Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease , 2016 .

[12]  A. Hauschild,et al.  Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. , 2016, The New England journal of medicine.

[13]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[14]  Antoni Ribas,et al.  The “cancer immunogram” , 2016, Science.

[15]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[16]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[17]  P. Ascierto,et al.  Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. , 2015, The Lancet. Oncology.

[18]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[19]  S. H. van der Burg,et al.  Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response , 2014, Science Translational Medicine.

[20]  P. Ascierto,et al.  Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Stratton,et al.  Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Emerson,et al.  Using synthetic templates to design an unbiased multiplex PCR assay , 2013, Nature Communications.

[23]  R. Fisher,et al.  Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. , 2012, The Lancet. Oncology.

[24]  C. Desmarais,et al.  Ultra-sensitive detection of rare T cell clones. , 2012, Journal of immunological methods.

[25]  T. Alderliesten,et al.  Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer , 2010, The British journal of surgery.

[26]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Abigail Wacher,et al.  Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. , 2009, Blood.

[28]  T. Schumacher,et al.  Design and use of conditional MHC class I ligands , 2006, Nature Medicine.

[29]  Tasuku Honjo,et al.  PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.

[30]  N Cascinelli,et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Blajchman,et al.  Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy. , 1975, British Journal of Cancer.